Diane Baniewicz, RN, MSN, CRNP
Locations: Main Hospital
Appointments and Referrals: 1-800-TRY-CHOP (1-800-879-2467)
Skip to content
My role is to coordinate and provide clinical care to children and families receiving treatment for high risk neuroblastoma. I especially enjoy coordinating care for international, out-of-state and locally based families seeking treatment options for this rare disease. I have a clinical focus on early phase clinical trials and 131I MIBG therapy. I enjoy the ongoing collaboration with families, referring physicians and the multidisciplinary team at CHOP to provide unique treatments to children with neuroblastoma.
Over the last 30 years that I have worked in pediatric oncology, I have been inspired by the resilience, strength and determination of children, young adults and their families during their journey after cancer diagnosis. Their experiences instill within me a personal determination to continue to strive to improve the care we provide to children and families.
I have presented posters and lectures that focus on the care of children with neuroblastoma, liver tumors and retinoblastoma. These presentations have focused on specific diseases and novel targeted therapies, immunotherapy, 131I MIBG therapy and symptom management for children and young adults diagnosed with neuroblastoma. My research interests are concentrated on education and preparation for patients and families receiving novel therapies for treatment of neuroblastoma.
Baniewicz D. Retinoblastoma [chapter revision]. In: Kline NE, editor. Essentials of pediatric hematology/oncology nursing: a core curriculum. 3rd ed. Glenview: Association for Pediatric Hematology/Oncology Nurses; 2009.
Children's Oncology Group
National Association of Pediatric Nurse Practitioners
Oncology Nursing Society
Johnson K, McGlynn B, Saggio J, Baniewicz D, Zhuang H, Maris JM, et al. Safety and efficacy of tandem (131) I-metaiodobenzylguanidine infusions in relapsed/refractory neuroblastoma. Pediatr Blood Cancer. Epub 2011 Apr 14. doi: 10.1002/pbc.23062. Cited in PubMed; PMIC 21495159. Read the abstract
Saggio J, Baniewicz D. Immunotherapy for neuroblastoma: how did we get here? Why are we doing it? What’s on the horizon? [oral presentation]. The Association of Pediatric Hematology/Oncology Nurses; 2011 Sep 8-10; Anaheim, CA.
Levy E, Baniewicz D, Ely E, Hyman A, Wallace C. Developing an evidence based review project to assess the educational needs of newly diagnosed patients and families with retinoblastoma [poster presentation]. 34th Annual Meeting of the Association of Pediatric Hematology/Oncology Nurses (APHON); 2010 Oct 14-16; Minneapolis, MN.
Baniewicz D, Gingrich A, Saggio J. A novel approach to treating adolescents and young adults with recurrent high risk neuroblastoma: monthly low dose I 131-meta iodobenzylguanidine therapy [poster presentation]. 33rd Annual Meeting of the Association of Pediatric Hematology/Oncology Nurses (APHON); 2009 Mar;
Baniewicz D, Karley P, Nicholson C, Sesko L. Mentoring and clinical supervision: a team leader approach [poster presentation]. 27th Annual Meeting of the Association of Pediatric Oncology Nurses; 2003 Oct 9-11; Philadelphia, PA.
Baniewicz D. Nursing care of the child with histiocytosis [panel presentation]. 19th Annual Meeting of the International Histiocytosis Society; 2003 Nov; Philadelphia, PA.
Certified Pediatric Nurse Practitioner - Primary Care (CPNP-PC)Certified Pediatric Oncology Nurse (CPON)
BSN - LaSalle University, Philadelphia, PA
RN - Chestnut Hill Hospital School of Nursing, Philadelphia, PA
MSN/Pediatric Nurse Practitioner - Villanova University, Villanova, PA
Nurse Practitioner, Immunotherapy Team
Clinical research neuroblastoma
Phase 1 and 2 clinical trials
Immunotherapy for neuroblastoma
I MIBG therapy
The Patient Experience Rating is an average of all responses to the care provider related questions shown above from our nationally-recognized Press Ganey Patient Satisfaction Survey. Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.
Responses are measured on a scale of 1 to 5 with 5 being the best score.
We are committed to true transparency. However, to ensure the comments are fair and correctly attributed, we review each one before posting to the website. We exclude entire comments that disclose patient's protected health information, are off-topic, or include other confidential or inappropriate content. Comments will appear on provider bios only if providers have a minimum number of comments.
Comments are shared internally for education purposes to ensure that we are doing our very best for the patients and families for whom we are privileged to care.
The comments are submitted by patients and families and reflect their views and opinions. The comments are not endorsed by and do not reflect the views of Children’s Hospital of Philadelphia.